2023 World Conference on Lung Cancer (Posters)-EP12.01. Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients

EP12.01. Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients - PDF(Abstract)

Back to course

Pdf Summary

This study presented the real-world clinical outcomes of patients with metastatic non-small cell lung cancer (NSCLC) treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor. The study included 46 patients diagnosed with EGFR NSCLC between 2011 and 2022, who received osimertinib as a first-line treatment or after disease progression. The mean age of the patients was 68.3 years, with the majority being female and never-smokers. Most patients had EGFR exon 19 or exon 21 mutations.<br /><br />The results showed that osimertinib was effective in controlling the disease, with a disease control rate of 95.7% and an overall response rate of 74%. The median time to response was 10.2 weeks, and the median duration of treatment exposure was 17.3 months. The median progression-free survival was 20 months, and the median overall survival was 33.8 months. The 12, 24, and 36-month overall survival rates were 84%, 70%, and 46%, respectively.<br /><br />Osimertinib was well tolerated, with grade 1 skin toxicity and gastrointestinal side effects being the most common adverse effects. Grade 3 or higher adverse events were present in 15.2% of patients. The frequency of dose reduction and interruption due to adverse events was 13% and 6.5%, respectively.<br /><br />Overall, this real-life study demonstrated the effectiveness of osimertinib in patients with advanced EGFR NSCLC and provided important insights into its clinical practice beyond the clinical trial setting.

Asset Subtitle

Blanca Távara

Meta Tag

Speaker Blanca Távara

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

metastatic non-small cell lung cancer

osimertinib

EGFR tyrosine kinase inhibitor

first-line treatment

disease progression

EGFR exon 19

EGFR exon 21

disease control rate

overall response rate

progression-free survival